Blaise, D <br/><br/>
Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.  [electronic resource] 

 -  Bone marrow transplantation  1991 
 - 146 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bone Marrow Transplantation<br/>Combined Modality Therapy<br/>Drug Evaluation<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Interleukin-2--therapeutic use<br/>Leukemia--immunology<br/>Lymphoma--immunology<br/>Recombinant Proteins--therapeutic use<br/>Transplantation, Autologous